ReviewDrugs2015
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Apremilast therapy increases CD39Rheumatology international · 2026Observational
- Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease.Journal of clinical medicine · 2025Review
- Safety assessment of apremilast: real-world adverse event analysis from the FAERS database.Archives of dermatological research · 2025Article
- Nanomaterials-mediated adenosine pathway inhibition for strengthening cancer immunotherapy.Theranostics · 2025Review
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis.Clinical pharmacokinetics · 2024Review
- Article
- Difamilast for the treatment of atopic dermatitis.The Journal of international medical research · 2023Review
- Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection.Experimental dermatology · 2023Article
- An Empirical Quantitative Structure-Activity Relationship Equation Assists the Discovery of High-Affinity Phosphodiesterase 4D Inhibitors as Leads to PET Radioligands.Journal of medicinal chemistry · 2023Article
- Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis.Clinical, cosmetic and investigational dermatology · 2022Review
- The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages.Biochemistry and biophysics reports · 2021Article
- Nanoemulsions: A Review on the Conceptualization of Treatment for Psoriasis Using a 'Green' Surfactant with Low-Energy Emulsification Method.Pharmaceutics · 2021Review
- Recent Advances in Liposomal-Based Anti-Inflammatory Therapy.Pharmaceutics · 2021Review
- Phosphodiesterase-4 Inhibition in Psoriasis.Psoriasis (Auckland, N.Z.) · 2021Review
- The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios.Psoriasis (Auckland, N.Z.) · 2021Review
- Organic-photoredox-catalyzed three-component sulfonylative pyridylation of styrenes.RSC advances · 2020Article
- Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature.Dermatology and therapy · 2020Review
- Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits.The Journal of clinical and aesthetic dermatology · 2019Review
- Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.Journal of medicinal chemistry · 2019Article
- Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.BMJ case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apremilast (Otezla(®)) is an oral phosphodiesterase 4 inhibitor indicated for the twice-daily treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient populations has been assessed in two phase III clinical trial programmes (ESTEEM and PALACE). At 16 weeks in the two ESTEEM trials, apremilast reduced the severity and extent of moderate to severe plaque psoriasis, including nail, scalp and palmoplantar manifestations, versus placebo in adults, with these benefits generally being sustained over 52 weeks of treatment. Similarly, in three PALACE trials (PALACE 1-3), apremilast improved the signs and symptoms of PsA relative to placebo at 16 weeks in adults with active disease despite treatment with conventional synthetic and/or biologic disease-modifying anti-rheumatic drugs. These PsA benefits were generally sustained for up to 104 weeks of treatment; skin involvement, enthesitis and dactylitis also improved with the drug. Apremilast was generally well tolerated, with the most common adverse events being diarrhoea and nausea in the first year of treatment (usually occurring in the first 2 weeks after the first dose and resolving within 4 weeks) and nasopharyngitis and upper respiratory tract infection with continued treatment. Although further longer-term and comparative efficacy and tolerability data would be beneficial, the current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults.
Indexed as
Identifiers
26220911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.